Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 14.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 786,472 shares of the company's stock after acquiring an additional 100,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd. owned about 1.71% of Urogen Pharma worth $8,698,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of the stock. RTW Investments LP grew its position in shares of Urogen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after acquiring an additional 47,447 shares in the last quarter. Toronto Dominion Bank acquired a new position in shares of Urogen Pharma in the 4th quarter worth approximately $18,628,000. Vestal Point Capital LP grew its position in shares of Urogen Pharma by 307.5% in the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock worth $17,360,000 after acquiring an additional 1,230,000 shares in the last quarter. Acorn Capital Advisors LLC acquired a new position in shares of Urogen Pharma in the 4th quarter worth approximately $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Urogen Pharma by 2.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company's stock worth $14,667,000 after acquiring an additional 36,084 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.
Insider Transactions at Urogen Pharma
In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $7.37, for a total value of $38,043.94. Following the sale, the insider owned 153,378 shares of the company's stock, valued at $1,130,395.86. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.70% of the stock is currently owned by company insiders.
Urogen Pharma Stock Up 1.2%
URGN stock traded up $0.19 during trading on Monday, reaching $15.46. The stock had a trading volume of 2,314,531 shares, compared to its average volume of 1,111,437. Urogen Pharma has a one year low of $3.42 and a one year high of $17.00. The company's 50 day moving average is $10.37 and its two-hundred day moving average is $10.49. The company has a market capitalization of $714.25 million, a price-to-earnings ratio of -4.86 and a beta of 1.02.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The company had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. As a group, research analysts predict that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have weighed in on URGN shares. Guggenheim reaffirmed a "buy" rating and set a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Urogen Pharma in a research report on Tuesday, July 8th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Urogen Pharma in a research note on Monday, July 7th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $32.86.
View Our Latest Stock Report on Urogen Pharma
Urogen Pharma Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Further Reading
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
